1). Harrison C. Current trends in essential thrombocythaemia. Br J Haematol. 2002. 117:796–808.
Article
2). Rozman C., Giralt M., Feliu E., Rubio D., Cortés MT. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer. 1991. 67:2658–63.
Article
3). Murphy S., Peterson P., Iland H., Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol. 1997. 34:29–39.
4). Vardiman JW., Harris NL., Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002. 100:2292–302.
Article
5). Elliott MA., Tefferi A. Thrombosis and hemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2004. 128:275–90.
6). Thiele J., Kvasnicka HM. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol. 2003. 82:148–52.
Article
7). Baxter EJ., Scott LM., Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005. 365:1054–61.
Article
8). Campbell PJ., Green AR. Management of polycythemia vera and essential thrombocythemia hematology. (Am Soc Hematol Educ Program). 2005. 201–8.
9). Cortelazzo S., Viero P., Finazzi G., D'Emilio A., Rodeghiero F., Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990. 8:556–62.
Article
10). Besses C., Cervantes F., Pereira A, et al. Major vascular complications in essential thrombocythaemia: a study of the predictive factors in a series of 148 patients. Leukemia. 1999. 13:150–4.
11). Cho SJ., Shin DG., Lee KH, et al. Essential thrombocythemia: vascular complications and cardiovascular risk factors. Korean J Hematol. 1999. 34:608–13.
12). Jantunen R., Juvonen E., Ikkala E., Oksanen K., Anttila P., Ruutu T. The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia. Ann Hematol. 2001. 80:74–8.
Article
13). Shih LY., Lin TL., Lai CL, et al. Predictive values of X-chromosome inactivation patterns and clinicohematologic parameters for vascular complications in female patients with essential thrombocythemia. Blood. 2002. 100:1596–601.
Article
14). Cortelazzo S., Finazzi G., Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995. 332:1132–36.
Article
15). Finazzi G., Budde U., Michiels J. Bleeding time and platelet function in essential thrombocythemia and other myeloproliferative syndromes. Leuk Lymphoma. 1996. 22:71–8.
Article
16). Regev A., Stark P., Blikstein D., Lahav M. Thrombotic complications in essential thrombocythemia with relatively low platelet counts. Am J Hematol. 1997. 56:168–72.
Article
17). Landolfi R., Marchioli R., Patrono C. Mechanisms of bleeding and thrombosis in myeloproliferative disorders. Thromb Haemost. 1997. 78:617–21.
Article
18). Raszeja-Specht A., Skibowska A., Bieniaszewska M., Szutowicz A. Relationships between thrombohemor-rhagic complications and platelet function in patients with essential thrombocythaemia. Am J Hematol. 2001. 68:32–6.
Article
19). Johansson P., Ricksten A., Wennstrom L., Palmqvist L., Kutti J., Andreasson B. Increased risk for vascular complications in PRV-1 positive patients with essential thrombocythaemia. Br J Haematol. 2003. 123:513–6.
Article
20). Sterkers Y., Preudhomme C., Lai JL, et al. Acute myeloid leukemia and myelodysplastic syndomes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood. 1998. 91:616–22.
21). Gugliotta L., Marchioli R., Fiacchini M. Epidemiological, diagnostic, therapeutic and prognostic aspects of essential thrombocythaemia in a retrospective study of he GIMMC group in two thousand patients. Blood. 1997. 90:348a, abstract. 1523.
22). Storen EC., Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood. 2001. 87:863–6.
Article
23). Mazzucconi MG., Redi R., Bernasconi S, et al. A long-term study of young patients with essential thrombocythemia treated with anagrelide. Haematolo-gica. 2004. 89:1306–13.
24). Harrison CN., Campbell PJ., Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005. 353:33–45.
Article